ArticleFrontiers in microbiology2012
New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Guideline
- New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.Frontiers in microbiology · 2025Review
- Construction ofVaccines · 2023Article
- Fungal extracellular vesicle-mediated regulation: from virulence factor to clinical application.Frontiers in microbiology · 2023Review
- Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).Geburtshilfe und Frauenheilkunde · 2021Article
- A Study to Assess The Efficacy of Local Application of Oral Probiotic in Treating Recurrent Aphthous Ulcer and Oral Candidiasis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2019Article
- Review
- NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans.Scientific reports · 2017Article
- Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis.Frontiers in microbiology · 2017Review
- Immunobiological Activity of Synthetically Prepared Immunodominant Galactomannosides Structurally MimickingFrontiers in immunology · 2017Article
- Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.Advanced healthcare materials · 2016Article
- Mycobacterium tuberculosis Zinc Metalloprotease-1 Elicits Tuberculosis-Specific Humoral Immune Response Independent of Mycobacterial Load in Pulmonary and Extra-Pulmonary Tuberculosis Patients.Frontiers in microbiology · 2016Article
- Induction of caspase-11 by aspartyl proteinases of Candida albicans and implication in promoting inflammatory response.Infection and immunity · 2015Article
- Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).Geburtshilfe und Frauenheilkunde · 2015Article
- Fungal vaccines and immunotherapeutics.Cold Spring Harbor perspectives in medicine · 2014Review
- Article
- Evaluation of anti-Candida activity of Vitis vinifera L. seed extracts obtained from wine and table cultivars.BioMed research international · 2014Article
- Codetection of Trichomonas vaginalis and Candida albicans by PCR in urine samples in a low-risk population attended in a clinic first level in central Veracruz, Mexico.BioMed research international · 2013Article
- Vaccines and immunotherapy against fungi: the new frontier.Frontiers in microbiology · 2013Article
- News from the fungal front: wall proteome dynamics and host-pathogen interplay.PLoS pathogens · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The commensal fungus Candida albicans causes mucosal candidiasis in the rapidly expanding number of immunocompromised patients. Mucosal candidiasis includes oropharyngeal, esophageal, gastrointestinal, and vaginal infections. Vulvovaginal candidiasis (VVC) and antimycotic-refractory recurrent VVC is a frequent problem in healthy childbearing women. Both these mucosal infections can affect the quality of life and finding new therapeutical and preventive approaches is a challenge. A vaccine against candidal infections would be a new important tool to prevent and/or cure mucosal candidiasis and would be of benefit to many patients. Several Candida antigens have been proposed as vaccine candidates including cell wall components and virulence factors. Here we discuss the recent progress and problems associated with vaccination against mucosal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.